ORGANOGENESIS HOLDINGS INC. - CLASS A

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

08 May 2025 15:05:01 By Nasdaq GlobeNewswire

Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

11 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

07 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

27 Feb 2025 15:05:01 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

27 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Expands Manufacturing Capacity to Support Future Growth

22 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Commends Final LCDs

15 Nov 2024 08:25:44 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

12 Nov 2024 15:05:01 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

12 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

11 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

16 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

01 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

04 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results

08 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Organogenesis Shares ReNu® Program Update

08 Aug 2024 15:04:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

15 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

06 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results

09 May 2024 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

02 May 2024 06:00:01 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

16 Apr 2024 06:30:00 By Nasdaq GlobeNewswire